Source link : https://www.newshealth.biz/health-news/oral-semaglutide-cuts-cardiovascular-events-in-t2d/
Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo Nordisk announced. The topline results met the primary endpoint of the company’s multicenter, double-blinded, randomized SOUL trial of 9650 people with type 2 diabetes (T2D) and established cardiovascular disease and/or chronic kidney disease. About half […]
Author : News Health
Publish date : 2024-10-22 12:36:09
Copyright for syndicated content belongs to the linked Source.
